Juxtapid (Lomitapide Mesylate) Patent Expiration, LOE Window & CMS Spending

Juxtapid (Lomitapide Mesylate) by Chiesi Farmaceutici Spa: FDA Orange Book LOE 2041-07-29, 0 AB generics, $15.0M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Farmaceutici Spa
FDA Application & PathwayN203858 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-07-29
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.0M
2024 Medicare Part D Spend$7.0M
2024 Medicaid Spend$8.0M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 16.3% 2-yr change)